, TABLE OF CONTENT jn jn
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber ........................................................................ 4
jn jn jn jn jn jn jn jn jn jn
Chapter 2. Review of Basic Principles of Pharmacology ....................................................................................... 5
jn jn jn jn jn jn jn
Chapter 3. Rational Drug Selection...................................................................................................................... 11
jn jn jn jn
Chapter 4. Legal and Professional Issues in Prescribing ...................................................................................... 14
jn jn jn jn jn jn jn
Chapter 5. Adverse Drug Reactions ..................................................................................................................... 16
jn jn jn jn
Chapter 6. An Introduction to Pharmacogenomics............................................................................................... 19
jn jn jn jn jn
Chapter 7. Nutrition and Nutraceuticals ............................................................................................................... 22
jn jn jn jn
Chapter 8. Herbal Therapies ................................................................................................................................ 28
jn jn jn
Chapter 9. Cannabis ............................................................................................................................................. 31
jn jn
Chapter 10. Pharmacoeconomics ......................................................................................................................... 35
jn jn
Chapter 11. Drugs Affecting the Autonomic Nervous System............................................................................. 38
jn jn jn jn jn jn jn
Chapter 12. Drugs Affecting the Central Nervous System ................................................................................... 45
jn jn jn jn jn jn jn
Chapter 13. Drugs Affecting the Cardiovascular and Renal Systems................................................................... 53
jn jn jn jn jn jn jn jn
Chapter 14. Drugs Affecting the Respiratory System .......................................................................................... 61
jn jn jn jn jn jn
Chapter 15. Drugs Affecting the Hematological System ..................................................................................... 65
jn jn jn jn jn jn
Chapter 16. Drugs Affecting the Immune System: Vaccines and Immunoglobulins ............................................ 69
jn jn jn jn jn jn jn jn jn
Chapter 17. Drugs Affecting the Immune System: Immunomodulators............................................................... 75
jn jn jn jn jn jn jn
Chapter 18. Drugs Affecting the Gastrointestinal System.................................................................................... 77
jn jn jn jn jn jn
Chapter 19. Drugs Affecting the Endocrine System: Pancreatic Hormones and Antidiabetic Drugs ..................... 80
jn jn jn jn jn jn jn jn jn jn jn
Chapter 20. Drugs Affecting the Endocrine System: Pituitary, Thyroid, and Adrenal Drugs ............................... 83
jn jn jn jn jn jn jn jn jn jn jn
Chapter 21. Drugs Affecting the Reproductive System ....................................................................................... 86
jn jn jn jn jn jn
Chapter 22. Drugs Affecting the Bones and Joints ............................................................................................... 92
jn jn jn jn jn jn jn
Chapter 23. Drugs Affecting the Integumentary System ...................................................................................... 96
jn jn jn jn jn jn
Chapter 24. Drugs Used to Treat Bacterial Infections ........................................................................................ 101
jn jn jn jn jn jn jn
Chapter 25. Drugs Used to Treat Viral, Fungal, and Protozoal Infections .......................................................... 105
jn jn jn jn jn jn jn jn jn jn
Chapter 26. Drugs Used to Treat Inflammatory Processes ................................................................................. 108
jn jn jn jn jn jn jn
Chapter 27. Drugs Used to Treat Eye and Ear Disorders .................................................................................... 111
jn jn jn jn jn jn jn jn jn
Chapter 28. Anemia ........................................................................................................................................... 113
jn jn
Chapter 29. Anxiety and Depression.................................................................................................................. 116
jn jn jn jn
Chapter 30. Attention Deficit-Hyperactivity Disorder ....................................................................................... 120
jn jn jn jn
Chapter 31. Asthma and Allergy ........................................................................................................................ 122
jn jn jn jn
Chapter 32. Chronic Obstructive Pulmonary Disease ........................................................................................ 125
jn jn jn jn jn
Chapter 33. Contraception ................................................................................................................................. 127
jn jn
Chapter 34. COVID-19: Acute and Chronic ...................................................................................................... 130
jn jn jn jn jn
Chapter 35. Dermatological Conditions............................................................................................................. 134
jn jn jn
Chapter 36. Diabetes Management .................................................................................................................... 138
jn jn jn
Chapter 37. Gastroesophageal Reflux and Peptic Ulcer Disease........................................................................ 146
jn jn jn jn jn jn jn
Chapter 38. Headaches ...................................................................................................................................... 149
jn jn
Chapter 39. Heart Failure ................................................................................................................................... 153
jn jn jn
Chapter 40. HIV Disease and Acquired Immunodeficiency Syndrome ............................................................. 158
jn jn jn jn jn jn jn
Chapter 41. Menopausal Hormone Therapy ...................................................................................................... 161
jn jn jn jn
,Chapter 42. Hyperlipidemia ............................................................................................................................... 164
jn jn
Chapter 43. Hypertension .................................................................................................................................. 169
jn jn
Chapter 44. Hyperthyroidism and Hypothyroidism ........................................................................................... 174
jn jn jn jn
Chapter 45. Obesity ........................................................................................................................................... 177
jn jn
Chapter 46. Pain Management: Acute and Chronic Pain.................................................................................... 181
jn jn jn jn jn jn jn
Chapter 47. Pneumonia ...................................................................................................................................... 185
jn jn
Chapter 48. Sexually Transmitted Diseases and Vaginitis ................................................................................. 187
jn jn jn jn jn jn
Chapter 49. Substance Use Disorders ................................................................................................................ 190
jn jn jn jn
Chapter 50. Tuberculosis ................................................................................................................................... 195
jn jn
Chapter 51. Upper Respiratory Tract Infection, Pharyngitis, Sinusitis, Otitis Media, and Otitis Externa ............. 197
jn jn jn jn jn jn jn jn jn jn jn jn
Chapter 52. Urinary Tract Infections ................................................................................................................. 200
jn jn jn jn
Chapter 53. Women as Patients ......................................................................................................................... 203
jn jn jn jn
Chapter 54. Men as Patients ............................................................................................................................... 207
jn jn jn jn
Chapter 55. Pediatric Patients ............................................................................................................................ 209
jn jn jn
Chapter 57. Geriatric Patients ............................................................................................................................ 213
jn jn jn
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e jn jn jn jn Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
jn jn jn jn jn jn jn jn jn jn
MULTIPLE CHOICE jn
1. Nurse practitioner prescriptive authority is regulated by:
jn jn jn jn jn jn
A. The National Council of State Boards of Nursing
jn jn jn jn jn jn jn
B. The U.S. Drug Enforcement Administration
jn jn jn jn
C. The State Board of Nursing for each state
jn jn jn jn jn jn jn
D. The State Board of Pharmacy
jn jn jn jn
ANS: C j n PTS: j n j n 1
2. The benefits to the patient of having an advanced practice registered nurse (APRN) prescriber in
jn jn jn jn jn jn jn jn jn jn jn jn jn jn
clude:
A. Nurses know more about pharmacology than other prescribers because they take it bo
jn jn jn jn jn jn jn jn jn jn jn jn
th in their basic nursing program and in their APRN program.
jn jn jn jn jn jn jn jn jn jn
B. Nurses care for the patient from a holistic approach and include the patient in de
jn jn jn jn jn jn jn jn jn jn jn jn jn jn
cision-making regarding their care. jn jn jn
C. APRNs are less likely to prescribe narcotics and other controlled substances.
jn jn jn jn jn jn jn jn jn jn
D. APRNs are able to prescribe independently in all states, whereas a physician’s as
jn jn jn jn jn jn jn jn jn jn jn jn
sistant needs to have a physician supervising their practice.
jn jn jn jn jn jn jn jn
ANS: B j n PTS: j n j n 1
3. Clinical judgment in prescribing includes:
jn jn jn jn
A. Factoring in the cost to the patient of the medication prescribed
jn jn jn jn jn jn jn jn jn jn
B. Always prescribing the newest medication available for the disease process
jn jn jn jn jn jn jn jn jn
C. Handing out drug samples to poor patients jn jn jn jn jn jn
D. Prescribing all generic medications to cut costs jn jn jn jn jn jn
ANS: A j n PTS: j n j n 1
4. The process for choosing an effective drug for a disorder includes:
jn jn jn jn jn jn jn jn jn jn
A. Asking the patient what drug they think would work best for them
jn jn jn jn jn jn jn jn jn jn jn
B. Consulting nationally recognized guidelines for disease management jn jn jn jn jn jn
C. Prescribing medications that are available as samples before writing a prescription
jn jn jn jn jn jn jn jn jn jn
D. Following U.S. Drug Enforcement Administration guidelines for prescribing
jn jn jn jn jn jn jn
ANS: B j n PTS: j n j n 1
5. Nonintentional nonadherence of drug therapy may occur due to: jn jn jn jn jn jn jn jn
A. Belief that medication does not work
jn jn jn jn jn
B. Adverse drug reactions jn jn
C. Chronic conditions that require daily therapy jn jn jn jn jn
D. Forgetfulness or distraction jn jn
ANS: D j n PTS: j n j n 1
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber ........................................................................ 4
jn jn jn jn jn jn jn jn jn jn
Chapter 2. Review of Basic Principles of Pharmacology ....................................................................................... 5
jn jn jn jn jn jn jn
Chapter 3. Rational Drug Selection...................................................................................................................... 11
jn jn jn jn
Chapter 4. Legal and Professional Issues in Prescribing ...................................................................................... 14
jn jn jn jn jn jn jn
Chapter 5. Adverse Drug Reactions ..................................................................................................................... 16
jn jn jn jn
Chapter 6. An Introduction to Pharmacogenomics............................................................................................... 19
jn jn jn jn jn
Chapter 7. Nutrition and Nutraceuticals ............................................................................................................... 22
jn jn jn jn
Chapter 8. Herbal Therapies ................................................................................................................................ 28
jn jn jn
Chapter 9. Cannabis ............................................................................................................................................. 31
jn jn
Chapter 10. Pharmacoeconomics ......................................................................................................................... 35
jn jn
Chapter 11. Drugs Affecting the Autonomic Nervous System............................................................................. 38
jn jn jn jn jn jn jn
Chapter 12. Drugs Affecting the Central Nervous System ................................................................................... 45
jn jn jn jn jn jn jn
Chapter 13. Drugs Affecting the Cardiovascular and Renal Systems................................................................... 53
jn jn jn jn jn jn jn jn
Chapter 14. Drugs Affecting the Respiratory System .......................................................................................... 61
jn jn jn jn jn jn
Chapter 15. Drugs Affecting the Hematological System ..................................................................................... 65
jn jn jn jn jn jn
Chapter 16. Drugs Affecting the Immune System: Vaccines and Immunoglobulins ............................................ 69
jn jn jn jn jn jn jn jn jn
Chapter 17. Drugs Affecting the Immune System: Immunomodulators............................................................... 75
jn jn jn jn jn jn jn
Chapter 18. Drugs Affecting the Gastrointestinal System.................................................................................... 77
jn jn jn jn jn jn
Chapter 19. Drugs Affecting the Endocrine System: Pancreatic Hormones and Antidiabetic Drugs ..................... 80
jn jn jn jn jn jn jn jn jn jn jn
Chapter 20. Drugs Affecting the Endocrine System: Pituitary, Thyroid, and Adrenal Drugs ............................... 83
jn jn jn jn jn jn jn jn jn jn jn
Chapter 21. Drugs Affecting the Reproductive System ....................................................................................... 86
jn jn jn jn jn jn
Chapter 22. Drugs Affecting the Bones and Joints ............................................................................................... 92
jn jn jn jn jn jn jn
Chapter 23. Drugs Affecting the Integumentary System ...................................................................................... 96
jn jn jn jn jn jn
Chapter 24. Drugs Used to Treat Bacterial Infections ........................................................................................ 101
jn jn jn jn jn jn jn
Chapter 25. Drugs Used to Treat Viral, Fungal, and Protozoal Infections .......................................................... 105
jn jn jn jn jn jn jn jn jn jn
Chapter 26. Drugs Used to Treat Inflammatory Processes ................................................................................. 108
jn jn jn jn jn jn jn
Chapter 27. Drugs Used to Treat Eye and Ear Disorders .................................................................................... 111
jn jn jn jn jn jn jn jn jn
Chapter 28. Anemia ........................................................................................................................................... 113
jn jn
Chapter 29. Anxiety and Depression.................................................................................................................. 116
jn jn jn jn
Chapter 30. Attention Deficit-Hyperactivity Disorder ....................................................................................... 120
jn jn jn jn
Chapter 31. Asthma and Allergy ........................................................................................................................ 122
jn jn jn jn
Chapter 32. Chronic Obstructive Pulmonary Disease ........................................................................................ 125
jn jn jn jn jn
Chapter 33. Contraception ................................................................................................................................. 127
jn jn
Chapter 34. COVID-19: Acute and Chronic ...................................................................................................... 130
jn jn jn jn jn
Chapter 35. Dermatological Conditions............................................................................................................. 134
jn jn jn
Chapter 36. Diabetes Management .................................................................................................................... 138
jn jn jn
Chapter 37. Gastroesophageal Reflux and Peptic Ulcer Disease........................................................................ 146
jn jn jn jn jn jn jn
Chapter 38. Headaches ...................................................................................................................................... 149
jn jn
Chapter 39. Heart Failure ................................................................................................................................... 153
jn jn jn
Chapter 40. HIV Disease and Acquired Immunodeficiency Syndrome ............................................................. 158
jn jn jn jn jn jn jn
Chapter 41. Menopausal Hormone Therapy ...................................................................................................... 161
jn jn jn jn
,Chapter 42. Hyperlipidemia ............................................................................................................................... 164
jn jn
Chapter 43. Hypertension .................................................................................................................................. 169
jn jn
Chapter 44. Hyperthyroidism and Hypothyroidism ........................................................................................... 174
jn jn jn jn
Chapter 45. Obesity ........................................................................................................................................... 177
jn jn
Chapter 46. Pain Management: Acute and Chronic Pain.................................................................................... 181
jn jn jn jn jn jn jn
Chapter 47. Pneumonia ...................................................................................................................................... 185
jn jn
Chapter 48. Sexually Transmitted Diseases and Vaginitis ................................................................................. 187
jn jn jn jn jn jn
Chapter 49. Substance Use Disorders ................................................................................................................ 190
jn jn jn jn
Chapter 50. Tuberculosis ................................................................................................................................... 195
jn jn
Chapter 51. Upper Respiratory Tract Infection, Pharyngitis, Sinusitis, Otitis Media, and Otitis Externa ............. 197
jn jn jn jn jn jn jn jn jn jn jn jn
Chapter 52. Urinary Tract Infections ................................................................................................................. 200
jn jn jn jn
Chapter 53. Women as Patients ......................................................................................................................... 203
jn jn jn jn
Chapter 54. Men as Patients ............................................................................................................................... 207
jn jn jn jn
Chapter 55. Pediatric Patients ............................................................................................................................ 209
jn jn jn
Chapter 57. Geriatric Patients ............................................................................................................................ 213
jn jn jn
, Woo 1
Pharmacotherapeutics for APN Prescribers, 6e jn jn jn jn Ch01
Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
jn jn jn jn jn jn jn jn jn jn
MULTIPLE CHOICE jn
1. Nurse practitioner prescriptive authority is regulated by:
jn jn jn jn jn jn
A. The National Council of State Boards of Nursing
jn jn jn jn jn jn jn
B. The U.S. Drug Enforcement Administration
jn jn jn jn
C. The State Board of Nursing for each state
jn jn jn jn jn jn jn
D. The State Board of Pharmacy
jn jn jn jn
ANS: C j n PTS: j n j n 1
2. The benefits to the patient of having an advanced practice registered nurse (APRN) prescriber in
jn jn jn jn jn jn jn jn jn jn jn jn jn jn
clude:
A. Nurses know more about pharmacology than other prescribers because they take it bo
jn jn jn jn jn jn jn jn jn jn jn jn
th in their basic nursing program and in their APRN program.
jn jn jn jn jn jn jn jn jn jn
B. Nurses care for the patient from a holistic approach and include the patient in de
jn jn jn jn jn jn jn jn jn jn jn jn jn jn
cision-making regarding their care. jn jn jn
C. APRNs are less likely to prescribe narcotics and other controlled substances.
jn jn jn jn jn jn jn jn jn jn
D. APRNs are able to prescribe independently in all states, whereas a physician’s as
jn jn jn jn jn jn jn jn jn jn jn jn
sistant needs to have a physician supervising their practice.
jn jn jn jn jn jn jn jn
ANS: B j n PTS: j n j n 1
3. Clinical judgment in prescribing includes:
jn jn jn jn
A. Factoring in the cost to the patient of the medication prescribed
jn jn jn jn jn jn jn jn jn jn
B. Always prescribing the newest medication available for the disease process
jn jn jn jn jn jn jn jn jn
C. Handing out drug samples to poor patients jn jn jn jn jn jn
D. Prescribing all generic medications to cut costs jn jn jn jn jn jn
ANS: A j n PTS: j n j n 1
4. The process for choosing an effective drug for a disorder includes:
jn jn jn jn jn jn jn jn jn jn
A. Asking the patient what drug they think would work best for them
jn jn jn jn jn jn jn jn jn jn jn
B. Consulting nationally recognized guidelines for disease management jn jn jn jn jn jn
C. Prescribing medications that are available as samples before writing a prescription
jn jn jn jn jn jn jn jn jn jn
D. Following U.S. Drug Enforcement Administration guidelines for prescribing
jn jn jn jn jn jn jn
ANS: B j n PTS: j n j n 1
5. Nonintentional nonadherence of drug therapy may occur due to: jn jn jn jn jn jn jn jn
A. Belief that medication does not work
jn jn jn jn jn
B. Adverse drug reactions jn jn
C. Chronic conditions that require daily therapy jn jn jn jn jn
D. Forgetfulness or distraction jn jn
ANS: D j n PTS: j n j n 1
